Maxigen Biotech Inc - Asset Resilience Ratio
Maxigen Biotech Inc (1783) has an Asset Resilience Ratio of 12.37% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Maxigen Biotech Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Maxigen Biotech Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 1783 current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Maxigen Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 1783 total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$251.50 Million | 12.37% |
| Total Liquid Assets | NT$251.50 Million | 12.37% |
Asset Resilience Insights
- Moderate Liquidity: Maxigen Biotech Inc has 12.37% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Maxigen Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Maxigen Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.87% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Autek China Inc
SHE:300595 |
Medical Instruments & Supplies | 21.20% |
|
Jiangxi Sanxin Medtec Co Ltd
SHE:300453 |
Medical Instruments & Supplies | 13.70% |
|
QITIAN Technology Group Co Ltd
SHE:300061 |
Medical Instruments & Supplies | 0.00% |
|
Dentium
KO:145720 |
Medical Instruments & Supplies | 1.23% |
|
Interojo Inc
KQ:119610 |
Medical Instruments & Supplies | 6.55% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
Annual Asset Resilience Ratio for Maxigen Biotech Inc (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Maxigen Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.93% | NT$301.50 Million ≈ $9.50 Million |
NT$1.89 Billion ≈ $59.64 Million |
+15.83pp |
| 2024-12-31 | 0.09% | NT$1.50 Million ≈ $47.26K |
NT$1.58 Billion ≈ $49.86 Million |
-0.01pp |
| 2023-12-31 | 0.10% | NT$1.50 Million ≈ $47.26K |
NT$1.49 Billion ≈ $47.04 Million |
-0.61pp |
| 2022-12-31 | 0.71% | NT$10.32 Million ≈ $325.01K |
NT$1.45 Billion ≈ $45.61 Million |
-1.41pp |
| 2021-12-31 | 2.12% | NT$26.87 Million ≈ $846.62K |
NT$1.27 Billion ≈ $39.86 Million |
+0.75pp |
| 2020-12-31 | 1.37% | NT$13.13 Million ≈ $413.82K |
NT$956.47 Million ≈ $30.13 Million |
-12.55pp |
| 2019-12-31 | 13.92% | NT$165.05 Million ≈ $5.20 Million |
NT$1.19 Billion ≈ $37.35 Million |
-6.53pp |
| 2018-12-31 | 20.45% | NT$232.25 Million ≈ $7.32 Million |
NT$1.14 Billion ≈ $35.77 Million |
+9.31pp |
| 2017-12-31 | 11.15% | NT$123.05 Million ≈ $3.88 Million |
NT$1.10 Billion ≈ $34.78 Million |
-12.37pp |
| 2016-12-31 | 23.52% | NT$258.07 Million ≈ $8.13 Million |
NT$1.10 Billion ≈ $34.57 Million |
+4.13pp |
| 2015-12-31 | 19.39% | NT$226.53 Million ≈ $7.14 Million |
NT$1.17 Billion ≈ $36.81 Million |
-23.56pp |
| 2014-12-31 | 42.95% | NT$435.41 Million ≈ $13.72 Million |
NT$1.01 Billion ≈ $31.94 Million |
+11.95pp |
| 2013-12-31 | 31.00% | NT$314.50 Million ≈ $9.91 Million |
NT$1.01 Billion ≈ $31.96 Million |
+23.83pp |
| 2012-12-31 | 7.17% | NT$36.26 Million ≈ $1.14 Million |
NT$505.76 Million ≈ $15.93 Million |
-4.97pp |
| 2011-12-31 | 12.14% | NT$59.09 Million ≈ $1.86 Million |
NT$486.65 Million ≈ $15.33 Million |
+11.95pp |
| 2010-12-31 | 0.19% | NT$820.00K ≈ $25.83K |
NT$429.76 Million ≈ $13.54 Million |
-0.93pp |
| 2009-12-31 | 1.12% | NT$3.85 Million ≈ $121.36K |
NT$343.55 Million ≈ $10.82 Million |
-- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more